Overview

Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Certain percentage of MDS patients develop iron overload. Iron is known to participate in intracellular reactions that generate free radicals, inducing oxidative stress and apoptosis, which was found to be increased in MDS patients and consequently resulted in ineffective hematopoiesis. The aim of this study is to evaluate the antioxidant effect of the oral iron chelator Deferasirox -Exjade in low risk MDS patients with iron over load by evaluating changes in several oxidative stress parameters Certain percentage of MDS patients develop iron overload.
Phase:
Phase 4
Details
Lead Sponsor:
Wolfson Medical Center
Collaborators:
Hadassah Medical Organization
Sheba Medical Center
Soroka University Medical Center
Tel-Aviv Sourasky Medical Center
Treatments:
Deferasirox